The ongoing transition story hits another roadblock
25/05/22 -"Considering the group was already facing multiple headwinds – deteriorating generics pricing environment in the US, market share losses for its recently launched products and product launch delays – ..."
Pages
53
Language
English
Published on
25/05/22
You may also be interested by these reports :
12/11/26
The Q3 results exceeded consensus estimates, backed by the strong showing of Electronics (driven by demand from AI applications) and healthy support ...
11/11/26
The Q3 profitability materially surpassed expectations, backed by the strong momentum for migraine and depression/schizophrenia treatments. The ...
06/11/26
Genmab’s sales missed expectations, but profitability significantly exceeded expectations. Growth was driven by contributions from most offerings, ...
06/11/26
Sanofi’s growth in recent years has been single-handedly driven by its cornerstone immunology treatment Dupixent, though there has been some support ...